CAMBRIDGE, MASSACHUSSETTS — Skylark Bio, a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss and other monogenic disorders, announced that the first patient has been dosed in the SONIX Phase 1/2 clinical trial evaluating SKY-GJB2, the company’s investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a Phase 1/2 first-in-human dosing announcement with no safety or efficacy data yet; audiologists should monitor trial progress but nothing changes in current practice.
If proven safe and effective, gene therapy targeting GJB2 mutations could offer the first disease-modifying treatment for one of the most common causes of inherited hearing loss, fundamentally reshaping the audiology care pathway.
- 01Skylark Bio dosed the first patient in the SONIX Phase 1/2 trial of SKY-GJB2 gene therapy.
- 02GJB2 mutations are among the most common genetic causes of congenital (present-at-birth) hearing loss.
- 03SKY-GJB2 is designed to deliver a functional copy of the GJB2 gene to the inner ear.
- 04This is a Phase 1/2 trial, meaning it is primarily evaluating safety and early signs of efficacy.
- 05No clinical outcomes data are available yet; trial enrollment is ongoing.
SKY-GJB2 targets GJB2-related hereditary hearing loss via gene therapy.
press releaseunclearThe SONIX trial has dosed its first patient.
press releasesupported